For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Impairment of operating lease right-of-use assets and related property and equipment | - | 0 | 0 | - |
| Loss on disposal of property and equipment | - | 0 | 0 | -3 |
| Total revenue, net | 26,218 | 21,194 | 20,923 | 8,982 |
| Cost of sales | 24,568 | 28,643 | 24,445 | 17,951 |
| Research and development expenses, net | 21,210 | 27,892 | 27,430 | 26,734 |
| Selling, general and administrative expenses | 39,953 | 36,280 | 30,265 | 29,534 |
| Loss from operations | -59,513 | -71,621 | -61,217 | -65,240 |
| Other income, net | 100 | 84 | 135 | 129 |
| Foreign exchange (losses) gains, net | -2,667 | -911 | 1,499 | 1,181 |
| Interest income | 2,469 | 4,382 | 5,234 | 6,137 |
| Interest expense, net | 11,124 | 10,520 | -6,829 | 10,143 |
| Total other (expenses) income, net | -11,222 | -6,965 | 13,697 | -2,696 |
| Net loss before income tax | -70,735 | -78,586 | -47,520 | -67,936 |
| Income tax expense | 863 | 532 | 397 | 2,225 |
| Net loss | -71,598 | -79,118 | -47,917 | -70,161 |
| Foreign currency exchange translation adjustment | -1,130 | -5,868 | 18,990 | 10,668 |
| Unrealized holding (losses) gains on available-for-sale debt securities, net of tax of 0 and 0, respectively | -141 | 86 | -22 | 400 |
| Total other comprehensive (loss) income, net of tax | -1,271 | -5,782 | 18,968 | 11,068 |
| Total comprehensive loss | -72,869 | -84,900 | -28,949 | -59,093 |
| Basic EPS | -0.27 | -0.3 | -0.18 | -0.26 |
| Diluted EPS | -0.27 | -0.3 | -0.18 | -0.26 |
| Basic Average Shares | 266,143,425 | 266,141,431 | 266,141,411 | 266,126,548 |
| Diluted Average Shares | 266,143,425 | 266,141,431 | 266,141,411 | 266,126,548 |
Autolus Therapeutics plc (AUTL)
Autolus Therapeutics plc (AUTL)